|
A NOVEL MICROFLUIDIC DEVICE FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHIC
|
2R44CA139841-02A1
|
$633,309
|
PRABHAKARPANDIAN, BALABHASKAR
|
CFD RESEARCH CORPORATION
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
1R01CA168900-01
|
$332,000
|
Powell, Daniel
|
UNIVERSITY OF PENNSYLVANIA
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
5K08CA160660-02
|
$156,330
|
Kentsis, Alex
|
DANA-FARBER CANCER INSTITUTE
|
|
ADAM 17 and glioma-tumor progression and treatment
|
5R01CA129446-04
|
$291,849
|
JIANG, FENG
|
HENRY FORD HEALTH SYSTEM
|
|
Addressing Undruggable Targets Using Oligonucleotides and Small Molecules (PQ18)
|
1R21CA170332-01
|
$165,300
|
JULIANO, RUDOLPH
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Adenovirus-host interactions and in vivo virus targeting
|
5R01CA141439-04
|
$412,933
|
SHAYAKHMETOV, DMITRY
|
UNIVERSITY OF WASHINGTON
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIABC010984
|
$1,556,987
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
5R01CA138738-04
|
$381,617
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
|
1R01CA166961-01A1
|
$338,631
|
RAPOPORT, AARON
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIABC011415
|
$30,333
|
Kochenderfer, James
|
CCR (NCI)
|
|
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers
|
5R01CA152005-03
|
$295,874
|
Mohapatra, Shyam
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Antibody directed delivery of short interfering RNA for the treatment of ovarian
|
1K08CA163603-01A1
|
$170,631
|
PALANCA-WESSELS, MARIA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Antibody Neutralization of Therapeutic Viruses
|
5R01CA129966-05
|
$488,632
|
RUSSELL, STEPHEN
|
MAYO CLINIC
|
|
Antibody-mediated Gene Therapy for the Treatment of Cancer
|
5K01CA138559-04
|
$142,677
|
Daniels, Tracy
|
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
|
|
Aptamer targeting of osteopontin in hepatocellular cancer
|
1R21CA155306-01A1
|
$195,098
|
KUO, PAUL
|
LOYOLA UNIVERSITY CHICAGO
|
|
Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
|
5R01CA138503-04
|
$301,913
|
Giangrande, Paloma
|
UNIVERSITY OF IOWA
|
|
Aspects of MUC13 Mucin in Cancer
|
5R01CA142736-03
|
$307,413
|
Chauhan, Subhash
|
SANFORD RESEARCH/USD
|
|
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
|
1K08CA163941-01
|
$173,772
|
Moon, Edmund
|
UNIVERSITY OF PENNSYLVANIA
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIABC011413
|
$60,665
|
Kochenderfer, James
|
CCR (NCI)
|
|
Basis for Lymphomagenesis in Akt2 Transgenic Mice
|
5R01CA077429-13
|
$410,451
|
TESTA, JOSEPH
|
FOX CHASE CANCER CENTER
|
|
Biodegradable Polymers For DNA Vaccine Delivery
|
5R01CA129189-05
|
$298,540
|
WANG, CHUN
|
UNIVERSITY OF MINNESOTA
|
|
BRAIN TUMOR SPORE GRANT
|
3P50CA097257-10S1
|
$599,883
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
|
|
Cancer Center Training - Experimental Therapy Models
|
5T32CA009363-29
|
$218,388
|
LAND, HARTMUT
|
UNIVERSITY OF ROCHESTER
|
|
Career Development in Pediatric and Medical Oncology
|
5K12CA076930-14
|
$550,042
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Carolina Center of Cancer Nanotechnology Excellence
|
5U54CA151652-03
|
$2,484,269
|
DeSimone, Joseph
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Cell Prep Core
|
ZICBC010905
|
$1,011,774
|
Wunderlich, John
|
CCR (NCI)
|
|
Cell Production Facility Core
|
ZICBC011020
|
$1,011,773
|
Dudley, Mark
|
CCR (NCI)
|
|
Center for Molecular Imaging Research at MGH/HMS
|
5P50CA086355-13
|
$1,358,452
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Center for Translational Cancer Nanomedicine
|
5U54CA151881-03
|
$2,529,540
|
TORCHILIN, VLADIMIR
|
NORTHEASTERN UNIVERSITY
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-04
|
$1,917,582
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZICBC010989
|
$335,259
|
Feldman, Steven
|
CCR (NCI)
|
|
Clinical Scholars Biomedical Research Training Program
|
5T32CA009512-26
|
$232,458
|
KELLY, THOMAS
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Combination Gene Therapy and Th1/Th2 Therapy
|
ZIABC011219
|
$236,816
|
Fowler, Daniel
|
CCR (NCI)
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
5U01CA151452-03
|
$413,032
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Conditionally Replicative Adenoviral Vectors for Malignant Glioma
|
5R01CA122930-05
|
$302,688
|
LESNIAK, MACIEJ
|
UNIVERSITY OF CHICAGO
|
|
CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS
|
5P20CA151129-02
|
$700,000
|
GILLESPIE, G.
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Converting an Oncogene to an Apoptotic Factor by Manipulating Signal Sequences
|
5R01CA129528-05
|
$275,034
|
LIM, CAROL
|
UNIVERSITY OF UTAH
|
|
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia
|
5R01CA155367-02
|
$348,600
|
KORTYLEWSKI, MARCIN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cytokine modulated model growth inhibitory mechanisms
|
5R01CA105005-09
|
$261,818
|
KALVAKOLANU, DHAN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Cytokine Regulation of Normal and Neoplastic Hematopoietic Cell Growth
|
ZIABC009264
|
$196,346
|
Ruscetti, Francis
|
CCR (NCI)
|
|
Designing Lymph Nodes for Cancer Immunotherapy
|
5R01CA148995-03
|
$336,129
|
MULE, JAMES
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer
|
5R01CA138794-03
|
$260,852
|
Liang, Gangning
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Development and evaluation of apoptosis targeted therapies in lung cancer
|
ZIABC011049
|
$256,727
|
Kwong, King
|
CCR (NCI)
|
|
Development of Pro-SELEX Aptamer Selection Platform
|
2R44CA150490-02A1
|
$693,881
|
DEMPSEY, PAUL
|
CYNVENIO BIOSYSTEMS, INC.
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-09
|
$2,300,000
|
McDermott, David
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Dissecting Glioma Genesis through a Glial-Specific Mouse Model
|
5R01CA098503-07
|
$252,836
|
Zhang, Wei
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
DNA Replication Control and Its Application to Selective Killing of Cancer Cells
|
5R00CA136555-04
|
$241,529
|
Zhu, Wenge
|
GEORGE WASHINGTON UNIVERSITY
|
|
Dual Role of E2F1 in Tumorigenesis
|
5R01CA079648-13
|
$336,775
|
Johnson, David
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Durable CD4+ T-cell Tumor Immunity Following Gene-modified HPSC
|
5R01CA134014-04
|
$301,886
|
Touloukian, Christopher
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Elimination of residual malignancy by programmed systemic cytokine gene therapy
|
5R01CA098928-10
|
$311,816
|
LI, SHULIN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|